Retatrutide: The Next-Generation GLP-1 Peptide Guide

What is retatrutide?#

Retatrutide (LY3437943) is an investigational peptide developed by Eli Lilly. It is a triple receptor agonist — it simultaneously activates three receptors: GLP-1 (glucagon-like peptide-1), GIP (glucose-dependent insulinotropic polypeptide), and glucagon receptors. This triple mechanism distinguishes it from both semaglutide (GLP-1 only) and tirzepatide (GLP-1 + GIP). Retatrutide is administered as a once-weekly subcutaneous injection, like semaglutide and tirzepatide. It has a long half-life (~6 days) that supports weekly dosing. As of early 2026, retatrutide is in Phase 3 clinical trials (the TRIUMPH programme). It is not yet approved by the FDA or any other regulatory authority. Compounded versions labelled as retatrutide are circulating; the quality, composition, and safety of these preparations are unverified.

Triple-agonist mechanism: why glucagon matters#

Understanding why retatrutide may outperform tirzepatide requires understanding the role of each receptor: GLP-1 receptor activation: Reduces appetite, slows gastric emptying, improves insulin secretion in a glucose-dependent manner. The core mechanism of all GLP-1 drugs (semaglutide, tirzepatide, retatrutide). GIP receptor activation: Enhances insulin secretion from the pancreas, may reduce nausea associated with GLP-1 agonism, and appears to augment the weight loss effect of GLP-1 agonism. Added by tirzepatide and retatrutide. Glucagon receptor activation: This is the unique addition in retatrutide. Glucagon increases energy expenditure, promotes fat breakdown (lipolysis) in the liver, and reduces fat accumulation. Paradoxically, despite glucagon being associated with glucose raising in isolation, in combination with GLP-1 agonism, glucagon activation appears to enhance fat oxidation without causing hyperglycaemia. The combination of all three mechanisms is theorised to produce greater energy expenditure (glucagon) alongside reduced energy intake (GLP-1/GIP), creating a more complete metabolic intervention than dual agonism alone.

Phase 2 trial results#

The Phase 2 trial of retatrutide (published in The New England Journal of Medicine, 2023) enrolled 338 adults with obesity. Key findings: Weight loss at 48 weeks (highest dose, 12 mg): 24.2% reduction in body weight on average — the highest weight reduction ever recorded in a GLP-1 class trial at that timepoint. Dose-response relationship: Clear dose-response was observed across the tested doses (1, 2, 4, 8, 12 mg). The 12 mg dose produced the most pronounced effect. Comparison context: Semaglutide (Wegovy) produces ~15% at 68 weeks. Tirzepatide produces ~21% at 72 weeks. Retatrutide achieved ~24% at 48 weeks, suggesting a potentially superior rate and magnitude of weight loss. Cardiovascular markers: Improvements in lipid profiles (reduced triglycerides, LDL) and blood pressure were observed. Side effect profile: Similar to other GLP-1 agents — primarily GI (nausea, vomiting, diarrhoea). Heart rate increases were noted, consistent with glucagon receptor activation (a known class effect). Phase 3 is ongoing (TRIUMPH programme). Larger sample sizes will confirm long-term safety and efficacy, with particular scrutiny on the cardiovascular effects of glucagon co-agonism.

Phase 2 data is promising but preliminary. Phase 3 results and regulatory approval are required before retatrutide can be considered an established treatment.

Retatrutide vs tirzepatide vs semaglutide#

How does retatrutide compare to the currently approved options? Weight loss efficacy (based on available trial data): - Semaglutide: ~15% at 68 weeks - Tirzepatide: ~21% at 72 weeks - Retatrutide: ~24% at 48 weeks (Phase 2, smaller sample) Mechanism: - Semaglutide: GLP-1 agonist - Tirzepatide: GLP-1 + GIP agonist - Retatrutide: GLP-1 + GIP + glucagon agonist Approval status: - Semaglutide: FDA approved (Wegovy for obesity, Ozempic for T2D) - Tirzepatide: FDA approved (Zepbound for obesity, Mounjaro for T2D) - Retatrutide: Phase 3, not yet approved Availability: - Semaglutide: Widely available brand-name + compounded - Tirzepatide: Available brand-name + compounded - Retatrutide: Investigational only; compounded versions unverified For individuals already achieving good results on tirzepatide, there may be limited reason to consider an unapproved compound. For those who have not achieved target weight loss on approved agents, retatrutide may become a future option once Phase 3 data confirms the Phase 2 results.

Retatrutide is not approved for human use. Compounded preparations carry unknown risks. Do not use without medical supervision.

What to watch for: Phase 3 and regulatory timeline#

The TRIUMPH Phase 3 programme for retatrutide includes trials assessing obesity, type 2 diabetes, and cardiovascular outcomes. Key milestones to watch: Top-line Phase 3 obesity data: Expected in 2025–2026. This will determine whether the ~24% weight loss seen in Phase 2 holds up at scale and with longer follow-up. Cardiovascular outcomes trial: GLP-1 drugs must demonstrate cardiovascular safety. A MACE (major adverse cardiovascular events) trial is part of the programme. Heart rate elevation from glucagon agonism is a key area of scrutiny. Regulatory submission: If Phase 3 data is positive, Eli Lilly would file for FDA approval. Approval could realistically occur in 2026–2027 if the data supports it. Compounding pharmacy landscape: Compounded GLP-1s exist in a shifting regulatory environment. The FDA has moved to restrict compounded semaglutide and tirzepatide as shortages have resolved. Compounded retatrutide faces the same potential restrictions, in addition to the fundamental concern that the compound is not yet approved. For those tracking the evolving GLP-1 landscape, retatrutide represents the next step in an accelerating progression: from GLP-1 monotherapy → dual GLP-1/GIP → triple GLP-1/GIP/glucagon. Further compounds in development target additional mechanisms, including amylin, FGF21, and GLP-2 co-agonism.